# EDGAR Filing Document

**Accession Number:** 0001083446
**File Stem:** 0001104659-26-058914
**Filing Date:** 2026-5
**Character Count:** 8950
**Document Hash:** 322d3eb66b673386ccde7f5c5861de25
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-058914.hdr.sgml**: 20260512

**ACCESSION NUMBER**: 0001104659-26-058914

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 47

**CONFORMED PERIOD OF REPORT**: 20260512

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260512

**DATE AS OF CHANGE**: 20260512

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Astrana Health, Inc.
- **CENTRAL INDEX KEY:** 0001083446
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MANAGEMENT CONSULTING SERVICES [8742]
- **ORGANIZATION NAME:** 07 Trade & Services
- **EIN:** 870042699
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37392
- **FILM NUMBER:** 26965675

**BUSINESS ADDRESS:**
- **STREET 1:** 1668 S. GARFIELD AVENUE
- **STREET 2:** 2ND FLOOR
- **CITY:** ALHAMBRA
- **STATE:** CA
- **ZIP:** 91801
- **BUSINESS PHONE:** (626) 282-0288

**MAIL ADDRESS:**
- **STREET 1:** 1668 S. GARFIELD AVENUE
- **STREET 2:** 2ND FLOOR
- **CITY:** ALHAMBRA
- **STATE:** CA
- **ZIP:** 91801

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Apollo Medical Holdings, Inc.
- **DATE OF NAME CHANGE:** 20080715

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SICLONE INDUSTRIES INC
- **DATE OF NAME CHANGE:** 19990413

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **May 12, 2026**

**ASTRANA HEALTH, INC.**

(Exact Name of Registrant as Specified in Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37392** | **95-4472349** |
| (State or Other Jurisdiction | (Commission | (I.R.S. Employer |
| of Incorporation) | File Number) | Identification No.) |

---

**1668 S. Garfield Avenue, 2nd Floor, Alhambra, California 91801**

(Address of Principal Executive Offices) (Zip Code)

**(626) 282-0288**

Registrant's Telephone Number, Including Area Code

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.001 par value per share | ASTH | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

---

| | |
|:---|:---|
| **Item 7.01** | **Regulation FD Disclosure.** |

---

On May 12, 2026, Astrana Health, Inc. (the "Company") updated its corporate presentation that it intends to use in connection with presentations at conferences and meetings. The slides from the Company's corporate presentation are attached as [Exhibit 99.1](tm2614280d1_ex99-1.htm) to this Current Report on Form 8-K and are incorporated herein by reference. The Company does not undertake to update the information contained in the attached presentation materials.

The information contained in this Current Report on Form 8-K, including the exhibit referenced herein, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. Such information shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The furnishing of this information will not be deemed an admission as to the materiality of any information contained herein.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.** |

---

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit <br> No.** | **Description** |
| [99.1](tm2614280d1_ex99-1.htm) | [Investor Presentation (May 2026).](tm2614280d1_ex99-1.htm) |
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document). |

---

**Forward-Looking Statements**

This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. These statements include words such as "forecast," "guidance," "projects," "estimates," "anticipates," "believes," "expects," "intends," "may," "plans," "seeks," "should," or "will," or the negative of these words or similar words. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in each such statement. A number of important factors could cause actual results to differ materially from those included within or contemplated by the forward-looking statements, including the factors described in the Company's filings with the Securities and Exchange Commission, including the Company's last Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q. The Company does not undertake any responsibility to update any of these factors or to announce publicly any revisions to any of the forward-looking statements contained in this or any other document, whether as a result of new information, future events, or otherwise.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **ASTRANA HEALTH, INC.** | **ASTRANA HEALTH, INC.** |
| Date: May 12, 2026 | By: | /s/ Brandon K. Sim |
|  | Name: | Brandon K. Sim |
|  | Title: | Chief Executive Officer and President |

---

## Exhibit 99.1

**Exhibit 99.1**

![](tm2614280d1_ex99d1x01.jpg)

![](tm2614280d1_ex99d1x02.jpg)

![](tm2614280d1_ex99d1x03.jpg)

![](tm2614280d1_ex99d1x04.jpg)

![](tm2614280d1_ex99d1x05.jpg)

![](tm2614280d1_ex99d1x06.jpg)

![](tm2614280d1_ex99d1x07.jpg)

![](tm2614280d1_ex99d1x08.jpg)

![](tm2614280d1_ex99d1x09.jpg)

![](tm2614280d1_ex99d1x10.jpg)

M e d i c a r e M e d i c a i d C o m m e r c i al O th e r T h i r d P a r t i es F u l l - r i s k P art i a l - r i sk F u l l - r i s k P art i a l - r i sk C a p i t at i o n , n e t R i s k P o o l S et t l e m e n t s & I n c e nt i v e s M a n a g e m e n t F e e I n c o me F e e - f or - s er v i c e, n e t O th e r In c o me

![](tm2614280d1_ex99d1x11.jpg)

![](tm2614280d1_ex99d1x12.jpg)

![](tm2614280d1_ex99d1x13.jpg)

![](tm2614280d1_ex99d1x14.jpg)

![](tm2614280d1_ex99d1x15.jpg)

• • • • •

![](tm2614280d1_ex99d1x16.jpg)

Gr o w a d i f f ere n ti a t ed p r o v i d er ne t w o rk B e nd t he c o s t c u r ve I n v e s t i n p a ti e n t p r o gr a m s , p re v en t i v e c a re and c are m a nageme nt Car e E na b le m e nt Care Par t ners

![](tm2614280d1_ex99d1x17.jpg)

![](tm2614280d1_ex99d1x18.jpg)

2 0 2 1 2 0 2 2 2 0 2 3 2 0 2 4 2 0 2 5 Q 1 2 0 2 6 2 0 2 6 E Q 1 2 0 2 6 2 0 2 6 E

![](tm2614280d1_ex99d1x19.jpg)

![](tm2614280d1_ex99d1x20.jpg)

![](tm2614280d1_ex99d1x21.jpg)

![](tm2614280d1_ex99d1x22.jpg)

![](tm2614280d1_ex99d1x23.jpg)

1 0.0% 1.0% 2.0% 3.0% 4.0% 5.0% 6.0% 7.0% 8.0% 9.0% - $50.0 $10 0 .0 $15 0 .0 $20 0 .0 $25 0 .0 G & A ($ M) G & A % o f R e v e n ue F Y 2 0 2 3 F Y 2 0 2 4 F Y 2 0 2 5 Q 1 2 0 2 5 Q 1 2 0 26

![](tm2614280d1_ex99d1x24.jpg)

![](tm2614280d1_ex99d1x25.jpg)

![](tm2614280d1_ex99d1x26.jpg)

![](tm2614280d1_ex99d1x27.jpg)

![](tm2614280d1_ex99d1x28.jpg)

![](tm2614280d1_ex99d1x29.jpg)

![](tm2614280d1_ex99d1x30.jpg)

![](tm2614280d1_ex99d1x31.jpg)

![](tm2614280d1_ex99d1x32.jpg)

![](tm2614280d1_ex99d1x33.jpg)

![](tm2614280d1_ex99d1x34.jpg)

![](tm2614280d1_ex99d1x35.jpg)

investors@astranahealth.com